Yolanda Arias - Concepedia

Author

Yolanda Arias

Universidad de Valladolid

Also Known As

Y ARIAS, Y Arias, Yolanda Arias

Publications

177

Citations

H-Index

Concepts

All Affiliations

Universidad de Valladolid Centro de Investigaciones Biológicas Margarita Salas Consejo Superior de Investigaciones Científicas Universidad Complutense de Madrid

About

Yolanda Arias is an author at Universidad de Valladolid specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	139
2	Cell Biology	3	3	85
3	Immunology	2	2	54
4	Health Sciences	1	1	30
5	Biochemistry	1	1	30

Yolanda Arias

Publications

168

Citations

H-Index

Page 1

	Year	Citations
Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b Raquel Muñoz, Yolanda Arias, José M. Ferreras, Cancer Letters Cancer Cell LinesMedicineMolecular BiologyAnti-cancer AgentTumor Suppressor	2001	34
Non-toxic type 2 ribosome-inactivating proteins (RIPs) from Sambucus: occurrence, cellular and molecular activities and potential uses. Tomás Girbés, José M. Ferreras, Francisco Javier Arias, PubMed PhytoalexinProtein FunctionHealth SciencesBiochemistryCatalytic Inactivation	2003	30
Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b Raquel Muñoz, Yolanda Arias, José M. Ferreras, Cancer Letters MedicineImmunologyPathologyImmune Checkpoint InhibitorTumour Neovasculature	2007	29
Cytotoxicity of an Ebulin l-Anti-Human CD105 Immunotoxin on Mouse Fibroblasts (L929) and Rat Myoblasts (L6E9) Cells Expressing Human CD105 Jorge A. Benítez, José M. Ferreras, Raquel Muñoz, Medicinal Chemistry	2005	29
In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours Raquel Muñoz, Yolanda Arias, José M. Ferreras, Cancer Immunology Immunotherapy Tumor BiologyAnti-mouse EndoglinCancer ImmunosurveillanceEarly StagesMelanoma	2012	25
Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice Manuel J. Gayoso, Raquel Muñoz, Yolanda Arias, Toxicology and Applied Pharmacology Specific Dose-dependent DamageLieberkühn CryptsMedicineType 2Pharmacotherapy	2005	21

Page 1